Literature DB >> 15603512

Epigenetics and cancer.

Mukesh Verma1, Padma Maruvada, Sudhir Srivastava.   

Abstract

Both genetics and epigenetics regulate gene expression in cancer. Regulation by genetics involves a change in the DNA sequence, whereas epigenetic regulation involves alteration in chromatin structure and methylation of the promoter region. During the initiation, development, and progression of cancer, a number of genes undergo epigenetic changes. Some of these changes can be used as biomarkers for early detection of cancer as well as to follow treatment. A panel of epigenetic biomarkers is preferred to a single biomarker in clinical assays. Changes in gene expression due to epigenetic regulation can be reversed by chemicals, and this approach opens up a novel approach in cancer prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15603512     DOI: 10.1080/10408360490516922

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  16 in total

Review 1.  The heritability of postpartum depression.

Authors:  Elizabeth J Corwin; Ruth Kohen; Monica Jarrett; Brian Stafford
Journal:  Biol Res Nurs       Date:  2010-05-07       Impact factor: 2.522

2.  High dynamic range characterization of the trauma patient plasma proteome.

Authors:  Tao Liu; Wei-Jun Qian; Marina A Gritsenko; Wenzhong Xiao; Lyle L Moldawer; Amit Kaushal; Matthew E Monroe; Susan M Varnum; Ronald J Moore; Samuel O Purvine; Ronald V Maier; Ronald W Davis; Ronald G Tompkins; David G Camp; Richard D Smith
Journal:  Mol Cell Proteomics       Date:  2006-05-09       Impact factor: 5.911

Review 3.  Genetic and epigenetic biomarkers in cancer : improving diagnosis, risk assessment, and disease stratification.

Authors:  Mukesh Verma; Daniela Seminara; Fernando J Arena; Christy John; Kumiko Iwamoto; Virginia Hartmuller
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

Review 4.  Epigenetic Biomarkers in Colorectal Cancer.

Authors:  Mukesh Verma; Vineet Kumar
Journal:  Mol Diagn Ther       Date:  2017-04       Impact factor: 4.074

5.  Assessment of promoter methylation and expression of SIX2 as a diagnostic and prognostic biomarker in Wilms' tumor.

Authors:  Dongjian Song; Lifang Yue; Gang Wu; Shanshan Ma; Lihua Guo; Heying Yang; Qiuliang Liu; Da Zhang; Ziqiang Xia; Lei Wang; Junjie Zhang; Wei Zhao; Fei Guo; Jiaxiang Wang
Journal:  Tumour Biol       Date:  2015-04-29

Review 6.  Cancer control and prevention by nutrition and epigenetic approaches.

Authors:  Mukesh Verma
Journal:  Antioxid Redox Signal       Date:  2012-01-30       Impact factor: 8.401

7.  The impact of OGG1, MTH1 and MnSOD gene polymorphisms on 8-hydroxy-2'-deoxyguanosine and cellular superoxide dismutase activity in myocardial ischemia-reperfusion.

Authors:  Bensu Karahalil; Elvin Kesimci; Esra Emerce; Tulin Gumus; Orhan Kanbak
Journal:  Mol Biol Rep       Date:  2010-11-21       Impact factor: 2.316

Review 8.  Epigenetic research in cancer epidemiology: trends, opportunities, and challenges.

Authors:  Mukesh Verma; Scott Rogers; Rao L Divi; Sheri D Schully; Stefanie Nelson; L Joseph Su; Sharon A Ross; Susan Pilch; Deborah M Winn; Muin J Khoury
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

Review 9.  Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling.

Authors:  Mukesh Verma; Muin J Khoury; John P A Ioannidis
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-12-14       Impact factor: 4.254

10.  Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.

Authors:  Alma Chavez-Blanco; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucia Taja-Chayeb; Lucely Cetina; Myrna Candelaria; David Cantu; Aurora Gonzalez-Fierro; Patricia Garcia-Lopez; Pilar Zambrano; Carlos Perez-Plasencia; Gustavo Cabrera; Catalina Trejo-Becerril; Enrique Angeles; Alfonso Duenas-Gonzalez
Journal:  Mol Cancer       Date:  2005-07-07       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.